These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28024696)

  • 21. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
    Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
    Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
    Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
    Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
    Hou J; Jiang D; Zhang J; Gavine PR; Xu S; Liu Y; Xu C; Huang J; Tan Y; Wang H; Lu Y; Zheng L; Hou Y; Tan L
    Hum Pathol; 2014 Feb; 45(2):352-8. PubMed ID: 24360885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.
    Daher S; Zer A; Tschernichovsky R; Yacobi R; Barshack I; Tsabari S; Rottenberg Y; Zick A; Gottfried T; Lobachov A; Marom EM; Urban D; Saad A; Gantz-Sorotsky H; Onn A; Bar J
    Lung Cancer; 2023 Apr; 178():229-236. PubMed ID: 36898331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA mutation status in Japanese lung cancer patients.
    Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Nov; 54(2):209-15. PubMed ID: 16930767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK1 and AKT2 mutations in Japanese lung cancer.
    Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
    J Thorac Oncol; 2010 May; 5(5):597-600. PubMed ID: 20354455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung.
    Qiong Z; Na WY; Bo W; Zhu Z; Ling P; Bo MH; Min TY; Lei Z; Na HD; Bo Z; Fang LJ; Seng ZS
    Lung Cancer; 2015 Feb; 87(2):117-21. PubMed ID: 25488863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
    Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
    Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
    J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.